Related Experiment Video
Updated: Aug 9, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
Management issues in patients coinfected with hepatitis C virus and HIV
1Division of Gastroenterology and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, USA.
Insights
Coinfection with HIV and hepatitis C (HCV) accelerates liver disease. Optimizing HAART is crucial for managing coinfected patients, as HCV treatments can impact CD4+ counts.
Area of Science:
- Hepatology and Virology
- Immunology and Infectious Diseases
Background:
- Coinfection with human immunodeficiency virus (HIV) significantly accelerates hepatitis C virus (HCV) progression to advanced liver disease.
- Low CD4+ cell counts in coinfected individuals can lead to false-negative diagnostic test results, underscoring the importance of HCV RNA assays.
Discussion:
- Optimizing highly active antiretroviral therapy (HAART) is the recommended first-line management for HIV-HCV coinfection due to the association between low CD4+ counts and increased liver fibrosis.
- Hepatitis C treatment agents may negatively affect CD4+ cell counts and hemoglobin levels, necessitating careful patient monitoring.
Key Insights:
- HCV RNA assays are essential for accurate viral load assessment in coinfected patients with low CD4+ counts.
- HAART optimization is critical for mitigating fibrosis progression in HIV-HCV coinfection.
Outlook:
- Long-acting interferons show potential for improved sustained virologic response in patients with HIV-HCV coinfection.
- Further research into managing coinfection is needed to optimize treatment strategies and patient outcomes.
Abstract:
Coinfection with HIV accelerates the progression of hepatitis C toward advanced liver disease. Low CD4+ cell counts may result in false-negative results on all diagnostic tests except hepatitis C virus (HCV) RNA assays, which are the gold standard for viral replication. First-line management of HIV-HCV--coinfected patients should be optimization of HAART, because low CD4+ cell counts have been associated with greater fibrosis. In addition, agents used to treat hepatitis C may lower CD4+ cell counts and hemoglobin levels. Long-acting interferons offer the promise of better sustained HCV response in HIV-HCV coinfection.
Related Concept Videos
Retrovirus Life Cycles
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Hepatitis
Cryptococcal Meningitis

